CL2017003260A1 - Dominios variables simples de inmunoglobulina contra proteína f de rsv. - Google Patents

Dominios variables simples de inmunoglobulina contra proteína f de rsv.

Info

Publication number
CL2017003260A1
CL2017003260A1 CL2017003260A CL2017003260A CL2017003260A1 CL 2017003260 A1 CL2017003260 A1 CL 2017003260A1 CL 2017003260 A CL2017003260 A CL 2017003260A CL 2017003260 A CL2017003260 A CL 2017003260A CL 2017003260 A1 CL2017003260 A1 CL 2017003260A1
Authority
CL
Chile
Prior art keywords
variable domains
isvds
simple variable
against rsv
rsv protein
Prior art date
Application number
CL2017003260A
Other languages
English (en)
Inventor
Xavier Saelens
Bert Schepens
Iebe Rossey
Barney Graham
Jason Mclellan
Morgan Gilman
Original Assignee
Vib Vzw
Univ Gent
Dartmouth College
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57545045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017003260(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP15178653.0A external-priority patent/EP3124042A1/en
Application filed by Vib Vzw, Univ Gent, Dartmouth College, Us Health filed Critical Vib Vzw
Publication of CL2017003260A1 publication Critical patent/CL2017003260A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A DOMINIOS VARIABLES SIMPLES DE INMUNOGLOBULINA (ISVDS) QUE SE DIRIGEN CONTRA VIRUS SINCICIAL RESPIRATORIO (RSV). MÁS ESPECÍFICAMENTE, SE REFIERE A ISVDS QUE SE UNEN CON LA FORMA DE PREFUSIÓN DE LA PROTEÍNA DE FUSIÓN (F) DE RSV. LA INVENCIÓN TAMBIÉN SE REFIERE AL USO DE ESTOS ISVDS PARA LA PREVENCIÓN Y/O EL TRATAMIENTO DE INFECCIONES POR RSV Y S COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN ESTOS ISVDS.</p>
CL2017003260A 2015-06-18 2017-12-18 Dominios variables simples de inmunoglobulina contra proteína f de rsv. CL2017003260A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562181522P 2015-06-18 2015-06-18
EP15178653.0A EP3124042A1 (en) 2015-07-28 2015-07-28 Immunoglobulin single variable domain antibody against rsv prefusion f protein
EP15191868 2015-10-28

Publications (1)

Publication Number Publication Date
CL2017003260A1 true CL2017003260A1 (es) 2018-05-11

Family

ID=57545045

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003260A CL2017003260A1 (es) 2015-06-18 2017-12-18 Dominios variables simples de inmunoglobulina contra proteína f de rsv.

Country Status (18)

Country Link
US (2) US10501528B2 (es)
EP (1) EP3313432A1 (es)
JP (1) JP6836760B2 (es)
KR (1) KR20180056631A (es)
CN (1) CN108472343B (es)
AU (1) AU2016277887B2 (es)
BR (1) BR112017027303A2 (es)
CA (1) CA2989378A1 (es)
CL (1) CL2017003260A1 (es)
HK (1) HK1254779A1 (es)
IL (1) IL256315B2 (es)
MA (1) MA42246A (es)
MX (1) MX394666B (es)
MY (1) MY192870A (es)
PH (1) PH12017502356B1 (es)
RU (1) RU2730671C2 (es)
UA (1) UA123584C2 (es)
WO (1) WO2016203052A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1254779A1 (zh) * 2015-06-18 2019-07-26 Vib Vzw 抗rsv融合前f蛋白的免疫球蛋白单可变结构域抗体
WO2019024979A1 (en) * 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
CN114805561B (zh) * 2019-08-02 2023-07-18 苏州高泓利康生物科技有限公司 针对呼吸道合胞病毒的蛋白结合分子
CN116063468A (zh) * 2022-08-30 2023-05-05 武汉班科生物技术有限公司 中和呼吸道合胞病毒的c-型单域抗体及应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025228370A1 (zh) * 2024-04-29 2025-11-06 星济生物(苏州)有限公司 中和呼吸道合胞病毒的抗原结合蛋白及其应用
CN120329397A (zh) * 2024-12-26 2025-07-18 北京华诺泰生物医药科技有限公司 一种呼吸道合胞病毒f蛋白突变体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
JP5711972B2 (ja) * 2007-12-24 2015-05-07 アイディー バイオメディカル コーポレイション オブ ケベック 組換えｒｓｖ抗原
ES2713864T3 (es) 2008-06-05 2019-05-24 Ablynx Nv Secuencias de aminoácidos dirigidas contra proteínas de la envuelta de un virus y polipéptidos que comprenden las mismas para el tratamiento de enfermedades virales
EP2438087B1 (en) * 2009-06-05 2017-05-10 Ablynx N.V. Trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2011064382A1 (en) * 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
HK1254779A1 (zh) * 2015-06-18 2019-07-26 Vib Vzw 抗rsv融合前f蛋白的免疫球蛋白单可变结构域抗体

Also Published As

Publication number Publication date
US11248039B2 (en) 2022-02-15
IL256315A (en) 2018-02-28
EP3313432A1 (en) 2018-05-02
JP2018524979A (ja) 2018-09-06
CA2989378A1 (en) 2016-12-22
CN108472343B (zh) 2021-12-10
PH12017502356A1 (en) 2018-06-25
AU2016277887B2 (en) 2022-06-09
AU2016277887A1 (en) 2018-01-18
MX2017016590A (es) 2018-11-09
BR112017027303A2 (en) 2018-09-04
UA123584C2 (uk) 2021-04-28
RU2730671C2 (ru) 2020-08-24
MA42246A (fr) 2018-05-02
MX394666B (es) 2025-03-21
RU2018101662A (ru) 2019-07-22
US20180179266A1 (en) 2018-06-28
JP6836760B2 (ja) 2021-03-03
MY192870A (en) 2022-09-13
RU2018101662A3 (es) 2019-11-06
US20200102374A1 (en) 2020-04-02
IL256315B2 (en) 2023-12-01
CN108472343A (zh) 2018-08-31
HK1254779A1 (zh) 2019-07-26
US10501528B2 (en) 2019-12-10
IL256315B1 (en) 2023-08-01
WO2016203052A1 (en) 2016-12-22
KR20180056631A (ko) 2018-05-29
PH12017502356B1 (en) 2018-06-25

Similar Documents

Publication Publication Date Title
CL2017003260A1 (es) Dominios variables simples de inmunoglobulina contra proteína f de rsv.
EA201892251A1 (ru) Стабилизированные растворимые f-белки rsv до слияния
CO2021006308A2 (es) Proteínas f de prefusión del vrs estabilizadas
CL2022000531A1 (es) Composiciones y métodos para el tratamiento de infecciones virales.
DK3597646T3 (da) Terapeutiske forbindelser egnede til den profylaktiske eller terapeutiske behandling af en hiv-virusinfektion
EA201890735A1 (ru) Модуляторы корового белка вируса гепатита b
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
MX392098B (es) Anticuerpos neutralizantes de poliomavirus.
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
EA201890235A1 (ru) Стабилизированные растворимые f-полипептиды rsv до слияния
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
EA201892702A1 (ru) Стабилизированные f-белки rsv до слияния
EP3509596C0 (en) NORKETOTIFEN FOR THE TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION
EA202091849A1 (ru) Тиазолидные соединения для лечения вирусных инфекций
UY37449A (es) Anticuerpos anti-chikv y usos de éstos
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
EP3493823C0 (en) POSTBIOTIC BASED COMPOUND FOR THE TREATMENT OF OCULAR INFLAMMATION
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
UY36801A (es) PROCEDIMIENTO PARA EL TRATAMIENTO O LA PREVENCION DE CONDICIONES INMUNES RELACIONADAS CON INFECCIONES UTILIZANDO UNA COMPOSICION QUE COMPRENDE IgM
DK3471732T3 (da) Liposomer til behandling af virusinfektioner
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
TR201910305T4 (tr) Viral enfeksiyonları tedavi etmek için bileşikler.
TH1601005264A (es)